Skip to main content
89 search results for:

Certolizumab pegol 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 03-07-2020 | Axial spondyloarthritis | News | Article
    News in brief

    Study demonstrates real-world effectiveness of certolizumab pegol for axSpA

    Treatment with certolizumab pegol is beneficial for patients with axial spondyloarthritis in real-world clinical practice, suggest findings from the CIMAX study.

  2. 28-05-2020 | Axial spondyloarthritis | News | Article

    Certolizumab pegol dose reduction feasible in axSpA remission

    Patients with early axial spondyloarthritis who achieve remission with certolizumab pegol can reduce their dose without increasing their risk for flares but should not stop treatment completely, show results of the phase 3b C-OPTIMISE trial.

  3. 11-11-2019 | Axial spondyloarthritis | ACR/ARP 2019 | Article

    Certolizumab pegol shows dual role for axSpA and acute anterior uveitis

    Certolizumab pegol significantly reduces the risk for acute anterior uveitis flare in patients with axial spondyloarthritis, show 48-week interim results from the C-VIEW trial.

  4. 27-01-2020 | Rheumatoid arthritis | News | Article

    CDAI nonresponse at 3 months predicts late certolizumab pegol failure in RA

    Real-world findings suggest that nonresponse to certolizumab pegol based on CDAI scores at 3 months is a good indicator that patients with rheumatoid arthritis are unlikely to achieve the therapeutic target of low disease activity at 1 year.

  5. 23-07-2019 | Axial spondyloarthritis | Feature | Article

    Into the clinic: Certolizumab pegol for nonradiographic axSpA

    medwireNews talks to Walter Maksymowych and Marina Magrey about the impact of the recent FDA approval of certolizumab pegol for nonradiographic axial spondyloarthritis, and why the approval happened so much later in the USA than in Europe.

  6. 23-07-2019 | Spondyloarthropathies | Highlight | Teaser
    medwireNews feature

    Into the clinic: Certolizumab pegol for nonradiographic axSpA

    medwireNews talks to Walter Maksymowych and Marina Magrey about the impact of the recent FDA approval of certolizumab pegol for nonradiographic axial spondyloarthritis, and why the approval happened so much later in the USA than in Europe.

  7. 29-03-2019 | Axial spondyloarthritis | News | Article
    approvalsWatch

    FDA approves certolizumab pegol for nonradiographic axSpA

    It also cautions that certolizumab pegol is not indicated for use in children.

  8. 19-03-2019 | Axial spondyloarthritis | Highlight | Teaser
    medwireNews top story

    Certolizumab pegol shows promise for nonradiographic axSpA

    The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

  9. 15-03-2019 | Axial spondyloarthritis | News | Article

    Certolizumab pegol shows promise for nonradiographic axSpA

    The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

  10. 19-04-2018 | Certolizumab pegol | News | Article

    ‘Reassuring’ data on certolizumab pegol use during pregnancy

    Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.

  11. 28-03-2018 | Psoriatic arthritis | News | Article
    News in brief

    Long-term RAPID-PsA results point to sustained efficacy of certolizumab pegol

    Open-label extension results from the RAPID-PsA trial suggest that the benefits of certolizumab pegol are maintained for up to 4 years among patients with psoriatic arthritis.

  12. 12-07-2018 | Takayasu arteritis | Article

    Certolizumab pegol in the treatment of Takayasu arteritis

    Novikov P et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key197

  13. 23-10-2017 | Certolizumab pegol | News | Article

    Findings support continued use of certolizumab pegol during pregnancy

    Results from a small cohort study suggest that pregnant women who are treated with the tumor necrosis factor inhibitor certolizumab pegol have minimal risk for placental transfer of the drug to their babies during late pregnancy.

  14. 22-10-2019 | Teaser
    ACR/ARP 2019 clinical trial recommendation

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

    Sunday,   November 10, 17:00–17:15. Georgia World Congress Center, Atlanta, USA Presenting author:  Irene van der Horst-Bruinsma, Netherlands TRIAL RESULTS PUBLISHED  | Read the full story What our Advisory Board said: This is an important analysis for those treating resistant uveitis where certolizumab may have shown efficacy. – Laura Coates, UK

  15. 23-01-2018 | Axial spondyloarthritis | News | Article

    Imaging results support long-term efficacy of certolizumab pegol for axial spondyloarthritis

    Patients with axial spondyloarthritis who are treated with certolizumab pegol experience a sustained reduction in spinal inflammation, follow-up imaging results from the RAPID-axSpA trial suggest.

  16. 03-08-2018 | Rheumatoid arthritis | Article

    Treatment of rheumatoid arthritis with certolizumab pegol: Results from PROACTIVE, a non-interventional study in the UK and Ireland

    The objective of this non-interventional study was to investigate the long-term safety and effectiveness of certolizumab pegol in patients with

  17. 01-05-2018 | Psoriatic arthritis | Article

    PGA×BSA: A measure of psoriasis severity tested in patients with active psoriatic arthritis and treated with certolizumab pegol

    Walsh JA et al. J Rheumatol 2018; Advance online publication. doi: 10.3899/jrheum.170244

  18. 10-08-2018 | Rheumatoid arthritis | Highlight | Teaser
    Journal article

    Clinical, ultrasound, and predictability outcomes following certolizumab pegol treatment (with methotrexate) in patients with moderate-to-severe rheumatoid arthritis: 52-week results from the CZP-SPEED study

    The aim of this trial was to assess the impact of certolizumab pegol treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes in Italian patients with rheumatoid arthritis [ read more ]. Sarzi-Puttini P et al. Adv Ther 2018. doi: 10.1007/s12325-018-0751-8

  19. 24-07-2018 | Rheumatoid arthritis | Article

    Clinical, ultrasound, and predictability outcomes following certolizumab pegol treatment (with methotrexate) in patients with moderate-to-severe rheumatoid arthritis: 52-week results from the CZP-SPEED study

    To assess the impact of certolizumab pegol treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes and to determine the

  20. 28-03-2017 | Rheumatoid arthritis | Article

    Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients

    In this study, Fleischmann et al. demonstrate that certolizumab pegol has an acceptable safety profile over the long term (up to 7 years), and is also effective in maintaining initial improvements in rheumatoid arthritis. Fleischmann R, van Vollenhoven RF, Vencovský J et al. Rheumatol Ther 2017;4:57–69. doi:10.1007/s40744-017-0060-8

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.